Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML

Slides:

Advertisements

Similar presentations

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

Advertisements

CT and PET imaging in non-small cell lung cancer

From: Permanent Loss of Cervical Spinal Cord Function Associated with Interscalene Block Performed under General Anesthesia Anesthes. 2000;93(6):

Dose-escalation patient response.

Immunologic effects of F16-IL2 therapy.

A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer

Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism Gerald A. Colvin, David Berz, Muthalagu.

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Anti-Hu encephalitis. Anti-Hu encephalitis. A 68-year-old man with chronic obstructive pulmonary disease presented with gradually worsening memory deficits.

A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer

A, baseline and 4-week PET scan from patient 2 (MET c

Volume 65, Issue 4, Pages (April 2014)

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Figure 1 Clinical case study

Nat. Rev. Urol. doi: /nrurol

Carmel G. Cronin, Michael Moore, Michael A. Blake

Figure 2 Temporal distribution of MOG antibody in serum of 2 relapsing patients with demyelinating diseases Temporal distribution of MOG antibody in serum.

Treatment of 7 patients with relapsed/refractory NK/T-cell lymphomas treated with pembrolizumab. Treatment of 7 patients with relapsed/refractory NK/T-cell.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Clinical responses in patients.

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Representative CT and PET/CT images of three patients with NSCLCs

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Axial CT scans of the chest. a) Before treatment

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Successful AZD9291 Therapy Based on Circulating T790M

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Axial CT images of midthoracic lesions

CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.

Autophagy restrains pancreatic inflammation and expression of pTBK1, CCL5, and PD-L1 in vivo. Autophagy restrains pancreatic inflammation and expression.

IL32 is highly expressed in mycosis fungoides lesional skin.

coTCRcys-transduced T cells control tumor growth in vivo.

BLITC reporter for monitoring of GvHD.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

Representative CT and PET/CT images of three patients with NSCLCs

Clinical benefit from combination limb infusion and CTLA-4 blockade.

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

Gamma camera images at 72 h of patient with T3N0M0 squamous cell cancer of the tongue base (patient 14). Gamma camera images at 72 h of patient with T3N0M0.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

The times at which cells irradiated with 9

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

A 54-year-old man with biopsy-proved hyperplastic hematopoietic bone marrow in the T11 vertebral body. A 54-year-old man with biopsy-proved hyperplastic.

Macroscopic observations of the mogamulizumab-induced skin-related AEs

Only IFNγ shows consistently increased mRNA expression in mycosis fungoides (MF) lesions. mRNA expression levels of various cytokines in the skin of healthy.

Lesions and healthy organs dosimetry.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Representative biodistribution pattern of 111In-CMD-193.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Measurements of the apoptotic response of CLL cells to radiation and the association with elevated genomic complexity. Measurements of the apoptotic response.

Serial CT scan images from patient with a partial response.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Examples of imaging data in patients.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

Therapeutic efficacy of MEK and RAF inhibition in patients with MAP2K1- and ARAF-mutant systemic histiocytic neoplasms. Therapeutic efficacy of MEK and.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML. A, the figure shows axial 18-FDG-PET/CT scans obtained at baseline before treatment initiation and 14 days after the first infusion (patient 1). Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML. A, the figure shows axial 18-FDG-PET/CT scans obtained at baseline before treatment initiation and 14 days after the first infusion (patient 1). Pretherapeutic images show disseminated hypermetabolic myelosarcomas (chloromas; SUVmax 14.1) in the left deep cervical area, in the mediastinum, in the hilum of the liver, in the mesentery, in the hilum of the right kidney, in the manubrium of the sternum, in the transverse process of the 9th thoracic vertebra, and subcutaneously in the left gluteal area. The two clinically most critical lesions (left cervical and hilum of the liver) were irradiated between day 4 and day 24 with a cumulative dose of 23.4 Gy in addition to systemic therapy. A complete metabolic response of irradiated and all nonirradiated AML manifestations occurred within 14 days of treatment initiation, which was paralleled by a good partial morphologic remission. B, signs of skin GVHD, which occurred during therapy with F16-IL2 in this patient. Christoph Schliemann et al. Cancer Immunol Res 2015;3:547-556 ©2015 by American Association for Cancer Research